In Q3 2025, VERIGRAFT reached an important stage of maturity as clinical data validation for the TECVI-1 Phase I/II trial was completed. This marks a key transition from early clinical results to regulatory readiness — confirming both data robustness and the company’s steady clinical progress.
The validated dataset now forms the foundation for final reporting and forthcoming interactions with regulatory authorities, paving the way for pivotal Phase II studies. During the quarter, VERIGRAFT also strengthened its intellectual property position through continued European validations and divisional filings, reinforcing long-term protection of the company’s core technologies.
In parallel, preparations advanced for new non-dilutive EU funding applications, aligned with VERIGRAFT’s strategy to support growth while maintaining a balanced financial structure.
As Q4 begins, the company remains focused on completing clinical reporting, advancing strategic partnerships, and preparing for the next phase of clinical development — moving steadily toward the commercialization of personalized tissue therapies for vascular disease.